SUPRIYANSESupriya Lifescience LimitedMediumPositive
Announced Wed, 27 May · 18:40 IST

Supriya Lifescience Limited has informed the Exchange that Board of Directors at its meeting held on May 27, 2026, recommended Final Dividend of Re. 1 per equity share.

Corporate Actions View source PDF

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+29.4%1-day move
₹811.00
prior close
₹887.30
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.3+3.6+3.7+6.1+29.4+12.7+11.2+17.6+16.5+18.5+14.9+19.4
Up moveDown movePending
AI summary

Supriya Lifescience Limited's Board of Directors met on May 27, 2026, and approved the audited financial results for Q4 and full year ended March 31, 2026. The company reported total income of Rs. 8,393.62 million, up from Rs. 7,063.00 million in the previous year, representing approximately 19% growth. Net profit after tax stood at Rs. 2,091.20 million versus Rs. 1,879.58 million in FY25, reflecting an 11% increase. Earnings per share improved to Rs. 25.98 from Rs. 23.35. The Board also recommended a final dividend of Rs. 1 per equity share (50% on face value of Rs. 2 each), subject to shareholder approval at the ensuing Annual General Meeting. The statutory auditors issued an unmodified opinion on the financial statements.

Likely market impact

The company demonstrated strong operational performance with double-digit revenue and profit growth. The dividend recommendation signals healthy cash generation and reflects management confidence in the business outlook. However, investors should note the dividend amount is modest and the record date is yet to be announced.